CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 135 enrolled
Drug / intervention
5FU +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00682786
NCT00682786Phase 2Completed
CompareCT.gov

Genotype-directed Neoadjuvant Chemoradiation for Rectal Carcinoma

Washington University School of Medicine·interventional·Posted May 22, 2008·Updated Oct 6, 2017

In Brief

A Phase 2 clinical trial evaluating 5FU, Radiation, and 2 other interventions for Rectal Carcinoma. Completed, enrolled 135 participants across 1 site.

Detailed Summary

Determine if genotype-directed neoadjuvant chemoradiation, using information from the thymidylate synthase promoter polymorphism, result in a greater degree of tumor downstaging in high risk patients compared to historical controls.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRectal Carcinoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 22, 2008
Enrollment StartOct 1, 2002
Primary CompletionDec 1, 2008
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 6.2 yearsPosted 18.1 years ago

Interventions

5FUdrug

Radiationradiation

Surgery of resectable lesionsprocedure

Irinotecandrug